GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS

GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS

Background: Gilteritinib (XOSPATA ®, Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ADMIRAL trial, gilteritinib was compared with the standard of care in (R/R) acute myeloid leukemia...

Full description

Saved in:
Bibliographic Details
Main Authors: Mehmet Hilmi DOGU, Ali Irfan Emre TEKGUNDUZ, Burak DEVECI, Gulten KORKMAZ, Melda COMERT, Omur Gokmen SEVINDIK, Osman YOKUS, Istemi SERIN
Format: Article
Language:English
Published: PAGEPress Publications 2023-04-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Gilteritinib
acute myeloid leukemia
early access
real-life
response
prognosis
Online Access:http://www.mjhid.org/index.php/mjhid/article/view/5305
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.mjhid.org/index.php/mjhid/article/view/5305

Similar Items